Lista de obras - Diana Wattie - Dominio Público Uruguay

Absence of Somatic SQSTM1 Mutations in Paget’s Disease of Bone

artículo científico publicado en 2009

Bisphosphonate space measurement and dosage requirement for intravenous clodronate treatment of Paget's disease.

artículo científico publicado en 2001

Bone metabolism during long-term treatment with imatinib

artículo científico publicado en 2013

Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.

artículo científico publicado en 2004

Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib

artículo científico publicado en 2009

Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial

artículo científico publicado en 2005

Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial

artículo científico publicado en 2012

Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms

artículo científico publicado en 2007

Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone

artículo científico publicado en 2016

Paget's disease of bone in New Zealand: continued decline in disease severity.

artículo científico publicado en 2004

Previous pet ownership and Paget's disease

artículo científico publicado en 1990

Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial

artículo científico publicado en 2010

Radiological assessment of Paget's disease of bone after treatment with the bisphosphonates EHDP and APD.

artículo científico publicado en 1987

The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women

scholarly article by Andrew Grey et al published July 2009 in Obstetrical and Gynecological Survey

The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women

artículo científico publicado en 2008

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial